Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bedside CD19 CAR T-cell therapy (The General Hospital of Western Theater Command)
- Development stage
- Unknown
- Lead developer
- General Hospital of Western Theater Command of PLA
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Bedside CD19 CAR T-cell therapy is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by The General Hospital of Western Theater Command. This specific product is characterized by its "bedside" or point-of-care manufacturing process, which is designed to occur within the treatment facility to potentially reduce the time and logistical complexity associated with centralized manufacturing. The therapy involves the genetic modification of a patient's own T cells to express a CAR that targets the B-lymphocyte antigen CD19, a protein expressed on the surface of most B-cell malignancies. Once re-infused, these engineered T cells recognize and eliminate CD19-positive leukemia cells. It is currently being evaluated in Phase 1 clinical trials for the treatment of adults with B-cell acute lymphoblastic leukemia (B-ALL).
- Other names
- CD19 CAR T cellsCD-19 CAR T cellsCD 19 CAR T cellsBedside CD19 CAR-Tautologous bedside CD19-directed chimeric antigen receptor T-cell therapy
02
Targets
Beyond the preview
Go deeper on Bedside CD19 CAR T-cell therapy (The General Hospital of Western Theater Command).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bedside CD19 CAR T-cell therapy (The General Hospital of Western Theater Command).